Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45521

1.

MRI-TRUS fusion guided prostate biopsy - initial experience and assessment of the role of contralateral lobe systematic biopsy.

Andras I, Crisan D, Cata E, Tamas-Szora A, Caraiani C, Coman RT, Bungardean C, Mirescu C, Coman I, Crisan N.

Med Ultrason. 2019 Feb 17;21(1):37-44. doi: 10.11152/mu-1705.

PMID:
30779829
2.

Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2: A Multicenter Study.

Choi MH, Kim CK, Lee YJ, Jung SE.

AJR Am J Roentgenol. 2019 Feb 19:1-8. doi: 10.2214/AJR.18.20498. [Epub ahead of print]

PMID:
30779662
3.

Impact of access to novel therapies on the initial management of castrate-resistant prostate cancer: an Australian multicentre study.

Kwan EM, Semira MC, Bergin ART, Muttiah C, Beck S, Anton A, Campbell D, Wong S, Rosenthal M, Gibbs P, Tran B.

Intern Med J. 2019 Feb 18. doi: 10.1111/imj.14262. [Epub ahead of print]

PMID:
30779277
4.

Prospective Serum Metabolomic Profiling of Lethal Prostate Cancer.

Huang J, Mondul AM, Weinstein SJ, Derkach A, Moore SC, Sampson JN, Albanes D.

Int J Cancer. 2019 Feb 18. doi: 10.1002/ijc.32218. [Epub ahead of print]

PMID:
30779128
5.

Claros System: A Rapid Microfluidics-Based Point-of-Care System for Quantitative Prostate Specific Antigen Analysis from Finger-Stick Blood.

Maj-Hes A, Sevcenco S, Szarvas T, Kramer G.

Adv Ther. 2019 Feb 18. doi: 10.1007/s12325-019-0888-0. [Epub ahead of print]

PMID:
30778908
6.

Clinicopathological predictors of positive 68Ga-PSMA-11 PET/CT in PSA-only recurrence of localized prostate cancer following definitive therapy.

Aydin AM, Haberal B, Artykov M, Bilen CY, Yazici S.

Ann Nucl Med. 2019 Feb 18. doi: 10.1007/s12149-019-01340-1. [Epub ahead of print]

PMID:
30778860
7.

Both sides of the scalpel: the patient and the surgeon view.

Fry S, Challacombe B.

Nat Rev Urol. 2019 Feb 18. doi: 10.1038/s41585-019-0153-y. [Epub ahead of print] Review.

PMID:
30778197
8.

Return to work after cancer. A multi-regional population-based study from Germany.

Arndt V, Koch-Gallenkamp L, Bertram H, Eberle A, Holleczek B, Pritzkuleit R, Waldeyer-Sauerland M, Waldmann A, Zeissig SR, Doege D, Thong MSY, Brenner H.

Acta Oncol. 2019 Feb 19:1-8. doi: 10.1080/0284186X.2018.1557341. [Epub ahead of print]

PMID:
30777496
9.

Evaluation of the most optimal multiparametric magnetic resonance imaging sequence for determining pathological length of capsular contact.

Onay A, Vural M, Armutlu A, Ozel Yıldız S, Kiremit MC, Esen T, Bakır B.

Eur J Radiol. 2019 Mar;112:192-199. doi: 10.1016/j.ejrad.2019.01.020. Epub 2019 Jan 22.

PMID:
30777210
10.

Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.

Zhang HC, Luo W, Wang Y.

J Immunother Cancer. 2019 Feb 18;7(1):47. doi: 10.1186/s40425-019-0532-1.

PMID:
30777137
11.

Blood and Dietary Magnesium Levels are not linked with lower Prostate Cancer Risk in Black or White Men.

Fowke JH, Koyama T, Dai Q, Zheng SL, Xu J, Howard LE, Freedland SJ.

Cancer Lett. 2019 Feb 15. pii: S0304-3835(19)30101-6. doi: 10.1016/j.canlet.2019.02.023. [Epub ahead of print]

PMID:
30776477
12.

The anti-apoptotic proteins NAF-1 and iASPP interact to drive apoptosis in cancer cells.

Iosub-Amir A, Bai F, Sohn YS, Song L, Tamir S, Marjault HB, Mayer G, Karmi O, Jennings PA, Mittler R, Onuchic JN, Friedler A, Nechushtai R.

Chem Sci. 2018 Nov 20;10(3):665-673. doi: 10.1039/c8sc03390k. eCollection 2019 Jan 21.

13.

Outcomes of Long-term Interval Rescreening with Low-Dose CT for Lung Cancer in Different Risk Cohorts.

Aggarwal R, Lam AC, McGregor M, Menezes R, Hueniken K, Tateishi H, O'Kane GM, Tsao MS, Shepherd FA, Xu W, McInnis M, Schmidt H, Liu G, Kavanagh J.

J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30112-1. doi: 10.1016/j.jtho.2019.01.031. [Epub ahead of print]

PMID:
30771523
14.

Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells.

Feng Y, Sessions EH, Zhang F, Ban F, Placencio-Hickok V, Ma CT, Zeng FY, Pass I, Terry DB, Cadwell G, Bankston LA, Liddington RC, Chung TDY, Pinkerton AB, Sergienko E, Gleave M, Bhowmick N, Jackson MR, Cherkasov A, Ronai ZA.

Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30084-9. doi: 10.1016/j.canlet.2019.02.012. [Epub ahead of print]

PMID:
30771432
15.

The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.

Terada N, Kamoto T, Tsukino H, Mukai S, Akamatsu S, Inoue T, Ogawa O, Narita S, Habuchi T, Yamashita S, Mitsuzuka K, Arai Y, Kandori S, Kojima T, Nishiyama H, Kawamura Y, Shimizu Y, Terachi T, Sugi M, Kinoshita H, Matsuda T, Yamada Y, Yamamoto S, Hirama H, Sugimoto M, Kakehi Y, Sakurai T, Tsuchiya N.

BMC Cancer. 2019 Feb 15;19(1):156. doi: 10.1186/s12885-019-5342-9.

16.

Optimization and Repeatability of Multipool Chemical Exchange Saturation Transfer MRI of the Prostate at 3.0 T.

Stephen Evans V, Torrealdea F, Rega M, Brizmohun Appayya M, Latifoltojar A, Sidhu H, Kim M, Kujawa A, Punwani S, Golay X, Atkinson D.

J Magn Reson Imaging. 2019 Feb 15. doi: 10.1002/jmri.26690. [Epub ahead of print]

PMID:
30770603
17.

Population-based outcomes of men with a single negative prostate biopsy: Importance of continued follow-up among older patients.

Sayyid RK, Alibhai SMH, Sutradhar R, Eberg M, Fung K, Klaassen Z, Goldberg H, Perlis N, Madi R, Terris MK, Urbach DR, Fleshner NE.

Urol Oncol. 2019 Feb 13. pii: S1078-1439(19)30051-1. doi: 10.1016/j.urolonc.2019.01.030. [Epub ahead of print]

PMID:
30770299
18.

Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine.

Schillaci O, Scimeca M, Trivigno D, Chiaravalloti A, Facchetti S, Anemona L, Bonfiglio R, Santeusanio G, Tancredi V, Bonanno E, Urbano N, Mauriello A.

Nucl Med Biol. 2019 Jan 19. pii: S0969-8051(18)30323-8. doi: 10.1016/j.nucmedbio.2019.01.003. [Epub ahead of print] Review.

PMID:
30770226
19.

[Epigenetic markers of early diagnostics of prostate cancer.]

Peshkov MN.

Klin Lab Diagn. 2018;63(10):605-609. doi: 10.18821/0869-2084-2018-63-10-605-609. Russian.

PMID:
30768880
20.

Driver Network as a Biomarker: Systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction.

Huang L, Brunell D, Stephan C, Mancuso J, He B, Thompson TC, Zinner R, Kim J, Davies P, Wong STC.

Bioinformatics. 2019 Feb 15. pii: btz109. doi: 10.1093/bioinformatics/btz109. [Epub ahead of print]

PMID:
30768150

Supplemental Content

Loading ...
Support Center